Search

Your search keyword '"Fang, Yueh-Fu"' showing total 187 results
Start Over Author "Fang, Yueh-Fu" Search Limiters Full Text
187 results on '"Fang, Yueh-Fu"'

4. IL-6 and TIMP-1 Correlated to Airway Pathogen Colonization and Predict Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis.

Author

Lin, Horng-Chyuan, Hsieh, Meng-heng, Lo, Yu-Lun, Huang, Hung-Yu, Huang, Shih-Wei, Huang, Chien-Da, Chang, Po-Jui, Lo, Chun-Yu, Lin, Ting-Yu, Fang, Yueh-Fu, Lin, Shu-Min, Lin, Chun-Yu, and Tsai, Ying-Huang

Subjects
FUNGAL cultures, BACTERIAL cultures, BRONCHIECTASIS, INTERLEUKIN-6, SPUTUM, FIBROSIS
Abstract

Background: Non-cystic fibrosis bronchiectasis is associated with airway pathogen colonization. We planned to investigate the inflammatory markers in patients with different airway pathogens and their correlation with disease severity. Methods: We enrolled patients aged between 20 and 75 from October 2021 to August 2022. All patients had sputum evaluation for bacterial and fungal cultures before enrollment, and were classified into four groups according to the culture results. Results: Forty-four patients with non-CF bronchiectasis and six controls were enrolled and categorized as follows: Group 1, no pathogens identified in sputum cultures (n = 14); Group 2, positive fungal culture results (n = 18); Group 3, positive P. aeruginosa culture results (n = 7); and Group 4, positive culture results for both fungi and P. aeruginosa (n = 5). Group 4 had significantly higher serum defensin α 1, IL-6 and tissue inhibitors of MMP (TIMP)-1 levels than group 1 patients. The serum levels of IL-6 and TIMP-1 were positively correlated with the FACED score and negatively correlated with distance-saturation product. Conclusion: Significantly higher levels of serum IL-6 and TIMP-1 were found in the patients who had concomitant fungal and P. aeruginosa colonization, and were closely related to clinical severity and may have important roles in disease monitoring. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis

Author

Chen, Wei-Dar, primary, Wu, Cheng-Hsiu, additional, Wu, Po-Yi, additional, Lin, Chang-Ping, additional, Ou, Liang-Shiou, additional, Hwang, De-Kuang, additional, Sheu, Shwu-Jiuan, additional, Chiang, Wei-Yu, additional, Chang, Yo-Chen, additional, Lin, Chun-Ju, additional, Chan, Wei-Chun, additional, Fang, Yueh-Fu, additional, Chien-Chieh Huang, Jerry, additional, Kao, Tzu-En, additional, Chiu, Fang-Yi, additional, Hsia, Ning-Yi, additional, and Hwang, Yih-Shiou, additional

Published
2024
Full Text
View/download PDF

6. Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

Author

Tung, Pi-Hung, primary, Chiu, Tzu-Hsuan, additional, Huang, Allen Chung-Cheng, additional, Ju, Jia-Shiuan, additional, Huang, Chi-Hsien, additional, Wang, Chin-Chou, additional, Ko, How-Wen, additional, Chung, Fu-Tsai, additional, Hsu, Ping-Chih, additional, Fang, Yueh-Fu, additional, Guo, Yi-Ke, additional, Kuo, Chih-Hsi Scott, additional, and Yang, Cheng-Ta, additional

Published
2024
Full Text
View/download PDF

7. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

Author

Liao, Hsin-Wei, Hsu, Jung-Mao, Xia, Weiya, Wang, Hung-Ling, Wang, Ying-Nai, Chang, Wei-Chao, Arold, Stefan T, Chou, Chao-Kai, Tsou, Pei-Hsiang, Yamaguchi, Hirohito, Fang, Yueh-Fu, Lee, Hong-Jen, Lee, Heng-Huan, Tai, Shyh-Kuan, Yang, Mhu-Hwa, Morelli, Maria P, Sen, Malabika, Ladbury, John E, Chen, Chung-Hsuan, Grandis, Jennifer R, Kopetz, Scott, and Hung, Mien-Chie

Subjects
Cell Line, Tumor, Animals, Humans, Mice, Mice, Nude, Colonic Neoplasms, Repressor Proteins, Neoplasm Transplantation, Signal Transduction, Methylation, Female, Protein-Arginine N-Methyltransferases, Heterografts, ErbB Receptors, Cetuximab, Cell Line, Tumor, Nude, Receptor, Epidermal Growth Factor, Immunology, Medical and Health Sciences
Abstract

Posttranslational modifications to the intracellular domain of the EGFR are known to regulate EGFR functions; however, modifications to the extracellular domain and their effects remain relatively unexplored. Here, we determined that methylation at R198 and R200 of the EGFR extracellular domain by protein arginine methyltransferase 1 (PRMT1) enhances binding to EGF and subsequent receptor dimerization and signaling activation. In a mouse orthotopic colorectal cancer xenograft model, expression of a methylation-defective EGFR reduced tumor growth. Moreover, increased EGFR methylation sustained signaling activation and cell proliferation in the presence of the therapeutic EGFR monoclonal antibody cetuximab. In colorectal cancer patients, EGFR methylation level also correlated with a higher recurrence rate after cetuximab treatment and reduced overall survival. Together, these data indicate that R198/R200 methylation of the EGFR plays an important role in regulating EGFR functionality and resistance to cetuximab treatment.

Published
2015

10. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells

Author

Nie, Lei, Wang, Ying-Nai, Hsu, Jung-Mao, Hou, Junwei, Chu, Yu-Yi, Chan, Li-Chuan, Huo, Longfei, Wei, Yongkun, Deng, Rong, Tang, Jun, Hsu, Yi-Hsin, Ko, How-Wen, Lim, Seung-Oe, Huang, Kebin, Chen, Mei-Kuang, Chiu, Tai-Jan, Cheng, Chien-Chia, Fang, Yueh-Fu, Li, Chia-Wei, Goverdhan, Aarthi, Wu, Hsing-Ju, Lee, Cheng-Chung, Wang, Wen-Ling, Hsu, Jennifer, Chiao, Paul, Wang, Shao-Chun, and Hung, Mien-Chie

Subjects
Original Article
Abstract

Nuclear epidermal growth factor receptor (EGFR) has been shown to be correlated with drug resistance and a poor prognosis in patients with cancer. Previously, we have identified a tripartite nuclear localization signal (NLS) within EGFR. To comprehensively determine the functions and underlying mechanism of nuclear EGFR and its clinical implications, we aimed to explore the nuclear export signal (NES) sequence of EGFR that is responsible for interacting with the exportins. We combined in silico prediction with site-directed mutagenesis approaches and identified a putative NES motif of EGFR, which is located in amino acid residues 736-749. Mutation at leucine 747 (L747) in the EGFR NES led to increased nuclear accumulation of the protein via a less efficient release of the exportin CRM1. Interestingly, L747 with serine (L747S) and with proline (L747P) mutations were found in both tyrosine kinase inhibitor (TKI)-treated and -naïve patients with lung cancer who had acquired or de novo TKI resistance and a poor outcome. Reconstituted expression of the single NES mutant EGFR(L747P) or EGFR(L747S), but not the dual mutant along with the internalization-defective or NLS mutation, in lung cancer cells promoted malignant phenotypes, including cell migration, invasiveness, TKI resistance, and tumor initiation, supporting an oncogenic role of nuclear EGFR. Intriguingly, cells with germline expression of the NES L747 mutant developed into B cell lymphoma. Mechanistically, nuclear EGFR signaling is required for sustaining nuclear activated STAT3, but not for Erk. These findings suggest that EGFR functions are compartmentalized and that nuclear EGFR signaling plays a crucial role in tumor malignant phenotypes, leading to tumorigenesis in human cancer.

Published
2023

13. The Impact of Higher Protein Intake in Patients with Prolonged Mechanical Ventilation

Author

Huang, Shih-Wei, primary, Lin, Horng-Chyuan, additional, Chou, Yu-Feng, additional, Lin, Ting-Yu, additional, Lo, Chun-Yu, additional, Huang, Hung-Yu, additional, Fang, Yueh-Fu, additional, Hsieh, Meng-Heng, additional, Lin, Shu-Min, additional, Lo, Yu-Lun, additional, Hsieh, Meng-Jer, additional, Kao, Kuo-Chin, additional, Lin, Chun-Yu, additional, and Huang, Chung-Chi, additional

Published
2022
Full Text
View/download PDF

16. Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study

Author

Li, Shih-Hong, primary, Wu, Min-Hsien, additional, Wang, Hung-Ming, additional, Hsu, Ping-Chih, additional, Fang, Yueh-Fu, additional, Wang, Chih-Liang, additional, Chu, Hui-Chun, additional, Lin, Hung-Chih, additional, Lee, Li-Yu, additional, Wu, Ching-Yang, additional, Yang, Cheng-Ta, additional, Chen, Jen-Shi, additional, and Hsieh, Jason Chia-Hsun, additional

Published
2022
Full Text
View/download PDF

19. Epidermal Growth Factor Receptor Potentiates MCM7-Mediated DNA Replication through Tyrosine Phosphorylation of Lyn Kinase in Human Cancers

Author

Huang, Tzu-Hsuan, Huo, Longfei, Wang, Ying-Nai, Xia, Weiya, Wei, Yongkun, Chang, Shih-Shin, Chang, Wei-Chao, Fang, Yueh-Fu, Chen, Chun-Te, Lang, Jing-Yu, Tu, Chun, Wang, Yan, Hsu, Ming-Chuan, Kuo, Hsu-Ping, Ko, How-Wen, Shen, Jia, Lee, Heng-Huan, Lee, Pei-Chih, Wu, Yun, Chen, Chung-Hsuan, and Hung, Mien-Chie

Published
2013
Full Text
View/download PDF

20. Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation

Author

Kuo, Chih-Hsi Scott, Chiu, Tzu-Hsuan, Tung, Pi-Hung, Huang, Chi-Hsien, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Ko, Ho-Wen, Hsu, Ping-Chih, Fang, Yueh-Fu, Guo, Yi-Ke, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Chiu, Tzu-Hsuan, Tung, Pi-Hung, Huang, Chi-Hsien, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Ko, Ho-Wen, Hsu, Ping-Chih, Fang, Yueh-Fu, Guo, Yi-Ke, and Yang, Cheng-Ta

Abstract

Background: Treatment outcome between afatinib alone or with bevacizumab in non-small cell lung cancer (NSCLC) patient with epidermal growth factor receptor (EGFR) mutation remains insufficiently reported. Methods: A total of 405 advanced NSCLC patients with sensitizing-EGFR mutation receiving first-line single-agent afatinib or with bevacizumab were grouped and propensity score-matched. Progression-free survival (PFS), overall survival (OS) and secondary T790M mutation were analyzed. Results: In the original cohort, 367 (90.6%) patients received afatinib treatment alone and 38 (9.4%) patients received afatinib plus bevacizumab. Patients who received bevacizumab combination were significantly younger (54.6 ± 10.9 vs. 63.9 ± 11.5; p < 0.001) compared to the afatinib alone group. After propensity score matching, the afatinib alone and afatinib plus bevacizumab groups contained 118 and 34 patients, respectively. A non-significantly higher objective response was noted in the afatinib plus bevacizumab group (82.4% vs. 67.8%; p = 0.133). In the propensity score-matched cohort, a bevacizumab add-on offered no increased PFS (16.1 vs. 15.0 months; p = 0.500), risk reduction of progression (HR 0.85 [95% CI, 0.52–1.40]; p = 0.528), OS benefit (32.1 vs. 42.0 months; p = 0.700), nor risk reduction of death (HR 0.85 [95% CI, 0.42–1.74] p = 0.660) compared to the single-agent afatinib. The secondary T790M rate in afatinib plus bevacizumab and afatinib alone groups was similar (56.3% vs. 49.4%, p = 0.794). Multivariate analysis demonstrated that EGFR L858R (OR 0.51 [95% CI, 0.26–0.97]; p = 0.044), EGFR uncommon mutation (OR 0.14 [95% CI, 0.02–0.64]; p = 0.021), and PFS longer than 12 months (OR 2.71 [95% CI, 1.39–5.41]; p = 0.004) were independent predictors of secondary T790M positivity. Conclusion: Bevacizumab treatment showed moderate efficacy in real-world, afatinib-treated NSCLC patients with EGFR-sensitizing mutation.

Published
2022

21. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

Author

Huang, Chi-Hsien, Ju, Jia-Shiuan, Chiu, Tzu-Hsuan, Huang, Allen Chung-Cheng, Tung, Pi-Hung, Wang, Chin-Chou, Liu, Chien-Ying, Chung, Fu-Tsai, Fang, Yueh-Fu, Guo, Yi-Ke, Kuo, Chih-Hsi Scott, Yang, Cheng-Ta, Huang, Chi-Hsien, Ju, Jia-Shiuan, Chiu, Tzu-Hsuan, Huang, Allen Chung-Cheng, Tung, Pi-Hung, Wang, Chin-Chou, Liu, Chien-Ying, Chung, Fu-Tsai, Fang, Yueh-Fu, Guo, Yi-Ke, Kuo, Chih-Hsi Scott, and Yang, Cheng-Ta

Abstract

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib improves survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed the outcome between EGFR mutation subtypes in a large afatinib-treated cohort in which 516 EGFR-mutated NSCLC patients receiving afatinib as front-line treatment. EGFR uncommon mutations include exon 20 insertion, de novo T790M of high or low allele frequency (dT790MHAF/dT790MLAF), non-T790M compound mutation and others, where EGFR exon 20 insertion and dT790MHAF were defined as type-I and the rest as type-II uncommon mutation. Four hundred and sixty-one (89.3%) and 55 (10.7%) patients were common and uncommon mutation, respectively. Exon 20 insertion and dT790MHAF patients demonstrated a significantly shortened progression-free survival (PFS) (2.6 and 4.1 months) compared to EGFR common mutation, dT790MLAF and other uncommon mutation patients (15.1, 27.0 and 18.4 months; P = 3 × 10−8). Type-I uncommon mutation was an independent predictor of PFS (HR 4.46 [95% CI, 2.60-7.64]; P <.001) and OS (HR 2.56 [95% CI, 1.37-4.75]; P =.003). EGFR L858R patients demonstrated a significantly higher CNS progression (cause-specific HR, 3.16; 95% CI 1.24-8.08; P =.016), and type-I uncommon mutation patients exhibited a significantly higher systemic progression (cause-specific HR, 4.95; 95% CI 2.30-10.60; P = 4.3 × 10−5). Tendencies of higher CNS and lower systemic progression were observed in type-II uncommon mutation patients. A PFS ≥ 12 months (OR 2.38 [95% CI, 1.18-4.89]; P =.016) and uncommon EGFR mutation (OR 0.08 [95% CI, 0.01-0.48]; P =.021) were independent predictors of secondary T790M. Afatinib-treated NSCLC patients presented an EGFR genotype-specific pattern of disease progression and outcome.

Published
2022

22. The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Author

Chiu Tzu-Hsuan, Tung, Pi-Hung, Huang, Chi-Hsien, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Ko, Ho-Wen, Hsu, Ping-Chih, Fang, Yueh-Fu, Guo, Yi-Ke, Kuo, Chih-Hsi Scottt, Yang, Cheng-Ta, Chiu Tzu-Hsuan, Tung, Pi-Hung, Huang, Chi-Hsien, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Ko, Ho-Wen, Hsu, Ping-Chih, Fang, Yueh-Fu, Guo, Yi-Ke, Kuo, Chih-Hsi Scottt, and Yang, Cheng-Ta

Abstract

Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) patients was lacking. 310 patients of advanced NSCLC with common EGFR mutation receiving first-generation EGFR-TKI monotherapy or with bevacizumab were included and propensity-score matched. Progression-free survival (PFS), overall survival (OS) and secondary T790M mutation were analysed. Patients receiving EGFR-TKI and bevacizumab were significantly younger, had better performance status and with high incidence of brain metastasis (55.8%). In the propensity-score matched cohort, PFS (13.5 vs. 13.7 months; log-rank p = 0.700) was similar between the two groups. The OS (61.3 vs. 34.2 months; log-rank p = 0.010) and risk reduction of death (HR 0.42 [95% CI 0.20–0.85]; p = 0.017) were significantly improved in EGFR-TKI plus bevacizumab group. Analysis of treatment by brain metastasis status demonstrated EGFR-TKI plus bevacizumab in patients with brain metastasis was associated with significant OS benefit compared to other groups (log-rank p = 0.030) and these patients had lower early-CNS and early-systemic progressions. The secondary T790M did not significantly differ between EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups (66.7% vs. 75.0%, p = 0.460). Forty-one (31.1%) and 31 (23.5%) patients received subsequent osimertinib and chemotherapy, respectively. The post-progression OS of osimertinib and chemotherapy were 22.1 and 44.9 months in EGFR-TKI plus bevacizumab group and were 10.0 and 14.1 months in EGFR-TKI monotherpay group, respectively. First-generation EGFR-TKI with bevacizumab improved treatment efficacy in real-world patients of NSCLC with EGFR mutation. Patients with brain metastasis received additional OS benefit from this treatment.

Published
2022

25. sj-docx-1-tam-10.1177_17588359221113278 – Supplemental material for Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Author

Lee, Suey-Haur, Lin, Yu-Ching, Chiu, Li-Chung, Ju, Jia-Shiuan, Tung, Pi-Hung, Huang, Allen Chung-Cheng, Li, Shih-Hong, Fang, Yueh-Fu, Chen, Chih-Hung, Kuo, Scott Chih-Hsi, Wang, Chin-Chou, Yang, Cheng-Ta, and Hsu, Ping-Chih

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221113278 for Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study by Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang and Ping-Chih Hsu in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

26. sj-docx-2-tar-10.1177_17534666221132731 – Supplemental material for Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

Author

Hsu, Ping-Chih, Chang, John Wen-Cheng, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Fang, Yueh-Fu, and Wu, Chiao-En

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tar-10.1177_17534666221132731 for Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations by Ping-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang and Chiao-En Wu in Therapeutic Advances in Respiratory Disease

Published
2022
Full Text
View/download PDF

29. Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation

Author

Kuo, Chih-Hsi Scott, primary, Chiu, Tzu-Hsuan, additional, Tung, Pi-Hung, additional, Huang, Chi-Hsien, additional, Ju, Jia-Shiuan, additional, Huang, Allen Chung-Cheng, additional, Wang, Chin-Chou, additional, Ko, Ho-Wen, additional, Hsu, Ping-Chih, additional, Fang, Yueh-Fu, additional, Guo, Yi-Ke, additional, and Yang, Cheng-Ta, additional

Published
2022
Full Text
View/download PDF

31. Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Author

Lee, Suey-Haur, primary, Lin, Yu-Ching, additional, Chiu, Li-Chung, additional, Ju, Jia-Shiuan, additional, Tung, Pi-Hung, additional, Huang, Allen Chung-Cheng, additional, Li, Shih-Hong, additional, Fang, Yueh-Fu, additional, Chen, Chih-Hung, additional, Kuo, Scott Chih-Hsi, additional, Wang, Chin-Chou, additional, Yang, Cheng-Ta, additional, and Hsu, Ping-Chih, additional

Published
2022
Full Text
View/download PDF

32. The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer.

Author

Chang, John Wen‐Cheng, Chang, Ching‐Fu, Huang, Chen‐Yang, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Fang, Yueh‐Fu, Hsu, Ping‐Chih, and Wu, Chiao‐En

Subjects
LUNG cancer prognosis, THERAPEUTIC use of antineoplastic agents, LUNG cancer, GENETIC mutation, BODY weight, EPIDERMAL growth factor receptors, ONCOGENES, AGE distribution, PROTEIN-tyrosine kinase inhibitors, CANCER patients, TREATMENT effectiveness, SEX distribution, BODY surface area, RESEARCH funding, TERMINATION of treatment, DRUG side effects, PROGRESSION-free survival, OVERALL survival, EVALUATION
Abstract

Background: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring the EGFR mutation. Patients experiencing intolerable adverse events (AEs) would discontinue EGFR‐TKIs. This study aimed to evaluate the impact of intolerable AEs and subsequent treatment on the survival of patients who discontinued EGFR‐TKIs. Patients: The data of advanced NSCLC patients treated with EGFR‐TKIs as frontline treatment at Chang Gung Memorial Hospitals from June 2014 to March 2018 were retrospectively reviewed. Results: A total of 2190 patients were enrolled and treated with frontline EGFR‐TKIs. In August 2021, 114 (5.2%) patients experienced intolerable AEs requiring discontinuation of EGFR‐TKIs. The time median of EGFR‐TKIs discontinuation was 2.56 months. Age >65 years, females, body weight, and body surface area were associated with the occurrence of intolerable AEs for patients treated with afatinib. Patients experiencing skin/paronychia/mucositis and abnormal liver function test had favorable survivals results. Patients who received subsequent EGFR‐TKIs treatment, experienced better progression‐free survival (PFS), total PFS (from frontline line EGFR‐TKIs), and overall survival (OS) compared to patients receiving chemotherapy or no treatment. Patients undergoing subsequent EGFR‐TKIs had better total PFS (median, 14.9 vs. 11.3 months, p = 0.013) and OS (median, 31.3 vs. 20.1 months, p = 0.001) than patients who did not discontinue because of AEs. Favorable OS was validated by propensity score matching. Conclusion: Patients experiencing intolerable AEs during EGFR‐TKI treatment should consider switching to an alternative EGFR‐TKI, which increase the survival results as compared to those patients who did not experience intolerable AEs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan.

Author

Chang, John Wen‐Cheng, Huang, Chen‐Yang, Fang, Yueh‐Fu, Chang, Ching‐Fu, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Hsu, Ping‐Chih, and Wu, Chiao‐En

Subjects
LUNG cancer prognosis, STATISTICS, GENETIC mutation, EPIDERMAL growth factor receptors, MULTIVARIATE analysis, RETROSPECTIVE studies, METASTASIS, PROTEIN-tyrosine kinase inhibitors, CANCER patients, AFATINIB, RESEARCH funding
Abstract

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGFR‐TKIs and prognostic factors for patients with NSCLC harboring uncommon EGFR mutations, which account for 10% of EGFR mutations. Methods: A total of 230 treatment‐naive patients with NSCLC harboring uncommon EGFR mutations treated with first‐line EGFR‐TKIs between 2011 and 2018 at four hospitals (belonging to four institutions, Linkou, Kaohsiung, Keelung, and Chiayi, of the Chang Gung Memorial Hospital) in Taiwan were retrospectively reviewed. Their clinicopathological characteristics, adverse events (AEs), objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), and overall survival (OS) were collected. Univariate and multivariate analyses were performed to identify potential prognostic factors for PFS. Results: Overall, patients who received afatinib (n = 62) had better PFS (median: 6.4 vs. 5.9 months, p = 0.022) and OS (median: 13.4 vs. 13.0 months, p = 0.008) than those who received gefitinib/erlotinib (n = 124), although no significant differences were observed for ORR (46.8% vs. 35.5%, p = 0.137) or DCR (59.7% vs. 58.9%, p = 0.916). Patients who received afatinib showed significantly higher ORR (58.3% vs. 31.3%, p = 0.027) but not DCR compared with gefitinib/erlotinib for major uncommon mutations. Afatinib trended toward better PFS and OS for major uncommon mutations and compound mutations. No EGFR‐TKIs were effective for most NSCLC patients with exon 20 insertions. Performance status, metastasis of the liver and pleura, and dose reduction were independent prognostic factors for PFS. Conclusion: Afatinib demonstrated better survival outcomes than gefitinib/erlotinib for NSCLC patients harboring major EGFR uncommon mutations and compound mutations. Performance status and metastatic sites may be useful for predicting PFS for major uncommon mutations and compound mutations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. sj-docx-1-tam-10.1177_17588359211035710 – Supplemental material for First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer

Author

Huang, Allen Chung-Cheng, Huang, Chi-Hsien, Ju, Jia-Shiuan, Chiu, Tzu-Hsuan, Tung, Pi-Hung, Wang, Chin-Chou, Liu, Chien-Ying, Chung, Fu-Tsai, Fang, Yueh-Fu, Guo, Yi-Ke, Kuo, Chih-Hsi Scott, and Yang, Cheng-Ta

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359211035710 for First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer by Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, Pi-Hung Tung, Chin-Chou Wang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo and Cheng-Ta Yang in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

42. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer

Author

Huang, Allen Chung-Cheng, primary, Huang, Chi-Hsien, additional, Ju, Jia-Shiuan, additional, Chiu, Tzu-Hsuan, additional, Tung, Pi-Hung, additional, Wang, Chin-Chou, additional, Liu, Chien-Ying, additional, Chung, Fu-Tsai, additional, Fang, Yueh-Fu, additional, Guo, Yi-Ke, additional, Kuo, Chih-Hsi Scott, additional, and Yang, Cheng-Ta, additional

Published
2021
Full Text
View/download PDF

44. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

Author

Hsu, Ping-Chih, primary, Huang, Chun-Yao, additional, Wang, Chin-Chou, additional, Kuo, Scott Chih-Hsi, additional, Chu, Chia-Hsun, additional, Tung, Pi-Hung, additional, Huang, Allen Chung-Cheng, additional, Wang, Chih-Liang, additional, Chiu, Li-Chung, additional, Fang, Yueh-Fu, additional, and Yang, Cheng-Ta, additional

Published
2020
Full Text
View/download PDF

45. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.

Author

Fang, Yueh‐Fu and Liu, Ping‐Chi

Abstract

Tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) are the standard treatment for lung cancer patients with activating EGFR mutation. The traditional direct polymerase chain reaction (PCR) has lower sensitivity in the detection of EGFR mutations in patient tissue samples. Whilst PCR amplification kits increase the sensitivity in detecting some types of EGFR mutations, not many types of rare mutations are found. Here, we report a patient who had lung adenocarcinoma harboring EGFR T751_I759delinsS mutation and had good response to afatinib initially and osimertinib after developing resistance to afatinib. This rare EGFR mutation was not detected by Scorpion and ARMS method but was found using the next‐generation sequencing method. There are less prospective trials in the treatment of lung adenocarcinoma with very rare EGFR mutations. Our case report could therefore provide clinical experience to the clinicians in the management of their patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis

Author

Hsieh,Meng-Heng, Lin,Chun-Yu, Wang,Chen-Yu, Fang,Yueh-Fu, Lo,Yu-Lun, Lin,Shu-Min, and Lin,Horng-Chyuan

Subjects
Infection and Drug Resistance
Abstract

Meng-Heng Hsieh,1,2,* Chun-Yu Lin,1–3,* Chen-Yu Wang,2 Yueh-Fu Fang,1–3 Yu-Lun Lo,1,2 Shu-Min Lin,1,2 Horng-Chyuan Lin1,2 1Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; 2Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; 3Department of Pulmonary and Critical Care, Saint Paul’s Hospital, Taoyuan, Taiwan *These authors contributed equally to this work Purpose: Pseudomonas aeruginosa is associated with pulmonary function decline and high disease severity in non-cystic fibrosis (CF) bronchiectasis. The prevalence of nontuberculous mycobacteria (NTM) in non-CF bronchiectasis patients has increased recently. This study investigated the impact of NTM with or without P. aeruginosa isolates in non-CF bronchiectasis patients.Patients and methods: Our retrospective study included 96 non-CF bronchiectasis patients from January 2005 to December 2014. We recorded the presentation, exacerbations, emergency department (ED) visits, hospitalization, serial pulmonary function, radiologic studies, and sputum culture results. All patients were followed up for at least 2 years.Results: The 96 patients were divided into four groups: patients with concomitant negative NTM and P. aeruginosa isolates (n=41; group 1), patients with positive NTM isolates (n=20; group 2), patients with positive P. aeruginosa isolates (n=20; group 3), and patients with concomitant positive NTM and P. aeruginosa isolates (n=15; group 4). Compared with group 1 patients, patients in groups 2 and 3 showed a significant decline in forced expiratory volume in 1 second (FEV1). They also had more frequent annual acute exacerbations (AE), ED visits, and hospitalization. Group 4 patients had the greatest FEV1 and forced vital capacity (FVC) decline and the most frequent AE, ED visits, and hospitalization.Conclusion: Concomitant NTM and P. aeruginosa isolates in non-CF bronchiectasis are associated with the greatest pulmonary function decline and the worst disease severity. This result suggested that early recognition and prompt treatment of concomitant NTM and P. aeruginosa isolates may improve the outcome in non-CF bronchiectasis patients. Keywords: nontuberculous mycobacteria, Pseudomonas aeruginosa, non-cystic fibrosis bronchiectasis

Published
2018

48. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer

Author

Lee, Pei-Chih, primary, Fang, Yueh-Fu, additional, Yamaguchi, Hirohito, additional, Wang, Wei-Jan, additional, Chen, Tse-Ching, additional, Hong, Xuan, additional, Ke, Baozhen, additional, Xia, Weiya, additional, Wei, Yongkun, additional, Zha, Zhengyu, additional, Wang, Yan, additional, Kuo, Han-Pin, additional, Wang, Chih-Wei, additional, Tu, Chih-Yen, additional, Chen, Chia-Hung, additional, Huang, Wei-Chien, additional, Chiang, Shu-Fen, additional, Nie, Lei, additional, Hou, Junwei, additional, Chen, Chun-Te, additional, Huo, Longfei, additional, Yang, Wen-Hao, additional, Deng, Rong, additional, Nakai, Katsuya, additional, Hsu, Yi-Hsin, additional, Chang, Shih-Shin, additional, Chiu, Tai-Jan, additional, Tang, Jun, additional, Zhang, Ran, additional, Wang, Li, additional, Fang, Bingliang, additional, Chen, Ting, additional, Wong, Kwok-Kin, additional, Hsu, Jennifer L., additional, and Hung, Mien-Chie, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results